Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock ...
SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public o...
SOUTH SAN FRANCISCO, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the promotion of Judy Fox, Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific Officer, Executive Vice President, Research & Development...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was on the decline last week, dropping from 3,269.13 points on Monday (June 10) to 3,238.69 points as of 2:08 p.m. EDT on Friday (June 14). Last week, Provention Bio (NASDAQ: PRVB ) announced a public offering of its common stock on Monday...
SOUTH SAN FRANCISCO, Calif., June 15, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chron...
Gainers: Amber Road (NYSE: AMBR ) +26% . Marathon Patent Group (NASDAQ: MARA ) +25% . Riot Blockchain (NASDAQ: RIOT ) +18% . P.A.M. Transportation Services (NASDAQ: PTSI ) +18% . Ocean Power Technologies (NASDAQ: OPTT ) +17% . Charles & Colvard (NASDAQ: CTHR ) +15% . ATA (N...
CymaBay Therapeutics ( CBAY ) : The company announced first quarter financial results, with management highlighting the fact that enrollment was completed one quarter ahead of schedule in the phase 2b study of seladelpar in NASH patients (52-week, dose-ranging trial). Topline data for chang...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Willie Quinn - Chief Financial Officer & Senior Vice President, Corporate Development Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief ...
Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q1 GAAP EPS of -$0.10 beats by $0.05. More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter e...
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc Com Company Name:
SNSS Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as...
There’s Blood In The Streets, But Opportunity Could Be Presenting Itself With Penny Stocks What’s your strategy for finding the best penny stocks to buy ? At the top of my mind, there are a few things to look at. One of them is industry sentiment. Several industries ha...
Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma Resulting patent to extend Viracta's intellectual property protection into at least 20...